Alpha-oxoglutarate inhibits the proliferation of immortalized normal bladder epithelial cells via an epigenetic switch involving ARID1A

Muhammad Shahid1, Nicole Gull2, Austin Yeon2, Eunho Cho3, Jooeun Bae3, Hyun Seok Yoon4, Sungyong You1, Hana Yoon4, Minjung Kim5, Benjamin P. Berman2 & Jayoung Kim1,3,6,7

Interstitial cystitis (IC) is a chronic urinary tract disease that is characterized by unpleasant sensations, such as persistent pelvic pain, in the absence of infection or other identifiable causes. We previously performed comprehensive metabolomics profiling of urine samples from IC patients using nuclear magnetic resonance and gas-chromatography/mass spectrometry and found that urinary α-oxoglutarate (α-OG), a tricarboxylic acid (TCA) cycle intermediate, reportedly functions to suppress the proliferation of immortalized normal human bladder epithelial cells. Here, we identified AT-rich interactive domain 1A (ARID1A), a key chromatin remodeler, as being hypomethylated and upregulated by α-OG treatment. This was done through EPIC DNA methylation profiling and subsequent biochemical approaches, including quantitative RT-PCR and western blot analyses. Furthermore, we found that α-OG almost completely suppresses ten-eleven translocation (TET) activity, but does not affect DNA methyltransferase (DNMT) activity. Altogether, our studies reveal the potential role of α-OG in epigenetic remodeling through its effects on ARID1A and TET expression in the bladder. This may provide a new possible therapeutic strategy in treating IC.
interaction, and quality of life, mainly due to chronic pelvic pain, frequent urination, and other symptoms\textsuperscript{10–12}. Despite the considerable burden of IC on public health, there is no diagnostic gold standard for IC. Urologists currently use the American Urological Association guidelines for diagnosing IC in the absence of other identifiable causes for symptoms (e.g., urinary tract infection and cancer). Therefore, clearer disease indicators and studies involving larger populations are needed to further our understanding of the molecular and cellular mechanisms behind IC. Current treatment options also remain suboptimal. Because so little is known regarding IC, palliative care is the only option available to patients.

In an effort to identify IC biomarkers, we have been keen on examining urine as a bio-resource; mainly because bodily fluid most proximal to a disease site provides a wealth of informative biomarkers\textsuperscript{13–15}. A series of our studies involving metabolic profiling revealed a list of candidate urinary biomarkers associated with IC. Previously, we used nuclear magnetic resonance (NMR) and liquid chromatography–mass spectrometry (LC–MS) to show substantial differences between the metabolic profiles of urine from IC patients and those of healthy control subjects\textsuperscript{16}. We found that α-oxoglutarate (α-OG) was significantly increased in IC patients. α-OG, also known as α-ketoglutarate, is a key Krebs cycle intermediate and regulator of cellular redox states\textsuperscript{17}. More recently, α-OG has been reported to function in epigenetic regulation, contributing to metabolic reprogramming and macrophage activation\textsuperscript{17,18}. Treatment with α-OG in bladder epithelial cells suppressed cell proliferation and was consistent with previous observations by other groups that found α-OG inhibited cell cycle transitions through the up or downregulation of p21\textsuperscript{Waf1/Cip1}, p27\textsuperscript{Kip1}, cyclin D1, and Rb. However, no functional impacts or mechanisms of urinary α-OG have been proposed in the setting of bladder wall abnormalities or diseases and no correlations have been previously described.

In this study, we examined the biological impact of increased levels of α-OG. Given that our previous global metabolomics profiling of IC patient urine suggested the possibility of finding non-invasive metabolic signatures, this study focused on gaining new insight into the mechanism of IC through investigating the biological meaning of upregulated α-OG. Here, our Infinium MethylationEPIC profiling revealed the bladder DNA methylome as being responsive to α-OG. Our findings provide evidence suggesting that α-OG may change the physiology of bladder epithelial cells at the epigenetic and metabolic levels.

**Materials and Methods**

**Cell Culture and Progregation Assay.** Immortalized normal human bladder epithelial cells, TRT-HU1, were maintained as described previously\textsuperscript{19}. The TRT-HU1 cell line was constructed and extensively characterized in previously published papers. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM), containing 10% fetal bovine serum (FBS, Invitrogen), 1% penicillin/streptomycin, and 1% L-glutamine (Sigma, St. Louis, MO) in a 37 °C humidified incubator with 5% CO\textsubscript{2}. TRT-HU1 cells were seeded in 10 cm culture plates at a density of 1 x 10\textsuperscript{5} cells in standard growth medium. When the cells reached approximately 80% confluence, they were treated and incubated with 10 mM of α-OG or vehicle for 72 h. For the crystal violet staining cell proliferation assay, cells were stained with 0.5% crystal violet (Sigma-Aldrich Corp., St. Louis, MO, USA) in 30% ethanol for 10 minutes at room temperature. The cells were lysed in a 1% SDS solution. The absorbance of the solution was measured using a microplate spectrophotometer at a wavelength of 595 nm.

**Epigenome-wide DNA methylation.** Methylation profiles were obtained using the Illumina Infinium HumanMethylationEPIC BeadChip kit, which assayed approximately 850,000 methylation sites per sample at a single nucleotide resolution\textsuperscript{20}. Methylation scores were computed as β-values, which took into account the ratio of methylated probe intensities and the overall probe intensities (methylated and un-methylated plus a constant, C = 100). β-values are between 0 and 1. Assays and validations were performed according to the manufacturer's recommendations.

**Bioinformatic analysis.** A data analysis pipeline was established using a combination of R Studio and Bioconductor. Illumina HumanMethylationEPIC data (IDAT files) were imported into the Bioconductor minfi package. Extension of minfi package to support EPIC arrays is described in previous literature\textsuperscript{21}. Background in the data was corrected using PreprocessNoob\textsuperscript{22}. No normalization was done. Data was mapped to the genome according to standards outlined by minfi. Annotations were added using IlluminaMethylationManifest, a class built within the minfi package. Volcano plots were constructed using the Bioconductor package, TCGAbiolinks\textsuperscript{23}. Heatmaps were created using the Bioconductor package, ComplexHeatmap\textsuperscript{24}. Differentially methylated genes (DMGs) were identified using a simple T-test comparing treated and un-treated groups. Additionally, we compared the mean methylation differences between two groups and only included probes that had a difference of 10%. Using the DAVID software (Ver. 6.8)\textsuperscript{25}, we performed functional enrichment analysis of the DMGs to identify cellular processes and pathways perturbed by α-OG treatment.

**Network analysis.** From the functional enrichment analysis, we identified the hypo-methylated genes as those involved in cellular processes, including cell-cell adhesion and chromatin remodeling. We then searched for interactions among the hypo-methylated genes using the STRING database\textsuperscript{26}. A network model was reconstructed with the interactions between these genes and visualized using Cytoscape (Ver. 3.4)\textsuperscript{27}. Node size represents degree centrality, which is the number of interactions in the network model, and edge thickness represents interaction scores, which are combined scores obtained from the STRING database\textsuperscript{26}. These combined scores were computed by adding the probabilities from different evidence of interactions in the database and correcting for the probability of randomly observing an interaction.

**Quantitative RT-PCR.** Total RNA was purified using the MagNA Pure Compact RNA isolation kit, according to the manufacturer's instructions (Roche). cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad). Q-PCR was carried out with iTaq universal SYBR green mix (BioRad) on a 7500 Fast Real-Time
PCR system (Life Technologies). The annealing temperature for the qPCR was set to 60 °C and the total cycle number was 40. Actb was used as internal control for gene expression normalization. Primers used for qRT-PCR assay are described in Supplementary Table 1.

Western blot analysis. Total cell lysates were prepared in lysis buffer (Bio-Rad) with protease inhibitors (Thermo Fisher). Protein levels were measured and 25 μg of cell lysates per condition were used for SDS-PAGE gel running. After transferring proteins to nitrocellulose membranes, western blot analysis was performed using antibodies specific for p53 (1:1000; sc-126; Santa Cruz), p21 (1:1000; 2947; Cell Signaling Technology), JunB (1:1000; 3746; Cell Signaling Technology), ARID1A (1:1000; 12354; Cell Signaling Technology), HDAC4 (1:1000; 5392; Cell Signaling Technology), PKD (1:1000; 2052; Cell Signaling Technology), β-catenin (1:1000; 8480; Cell Signaling Technology), PBRM1 (1:1000; 91894; Cell Signaling Technology), SMARCA2 (1:1000; 11966; Cell Signaling Technology), and β-actin (1:2000; A1978; Sigma-Aldrich). These were incubated overnight and followed by anti-specie-specific HRP-conjugated secondary antibodies (1:5000; 7074, 7076; Cell Signaling Technology) and then chemiluminescent detection. Some blots were stripped using Restore (Thermo Fisher) and detected using other primary antibodies.

DNA Methyltransferase (DNMT) and ten-eleven translation (TET) activity assay. Cells were seeded 24 h before experiments and incubated with α-OH-containing media for 20 h. A commercially available EpiQuik™ DNMT Activity/Inhibition Assay Ultra Kit (Epigentek, Farmingdale) was used to determine DNMT enzymatic activity as per the manufacturer’s instruction. For the TET activity assay, the Epigenase™ 5mC-Hydroxylase TET Activity/Inhibition Assay Kit (Colorimetric) was used, as per the manufacturer’s instructions. This sandwich-based 5hmC ELISA reads the conversion of methylated products to hydroxymethylated products through the presence of TET enzymes in samples.

Ethics statement. The Ethics Committee of Ewha Womans University Hospital (Seoul, Republic of Korea) approved this study. The Institutional Review Board of Ewha University Hospital approved collection, curation and analysis of all samples. All subjects participated in this study provided written informed consent, and all experiments were performed in accordance with relevant guidelines and regulations.

Subjects and biopsy tissue collection. Subjects, including IC patients (mean age, 52.5 ± 10.1) and healthy controls (mean age, 54.2 ± 9.3), were Asian-descent female residents in South Korea who were enrolled at their initial evaluation, before any treatments or procedures. They were diagnosed and recruited by two independent urologists, Drs. Hana Yoon and Hyun Seok Yoon, who have extensive clinical expertise in IC at an outpatient urology clinic at Ewha Womans University Hospital. Careful clinical diagnosis was done using clinical criteria in the AUA guidelines28,29, “An unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptom(s) of more than 6 weeks duration, in the absence of infection or other identifiable causes” (http://www.auanet.org/education/guidelines/ic-bladder-pain-syndrome.cfm). Diagnostic criteria included persistent or recurrent chronic pelvic pain, pressure or discomfort perceived to be related to the urinary bladder accompanied by at least one other urinary symptom such as an urgent need to void or urinary frequency in the absence of any identifiable pathology. Work-up included symptom assessment, cystoscopic evaluation, physical examination, urodynamics, and/or urine culture. Patients with a history of other diseases (such as any types of cancer, inflammation, or diabetes, etc.) were excluded. Patients who were under any active treatment or medication were clearly excluded. Only subjects >2 months “free of treatment, therapy, or any medications”, such as hormone use, pentosan polysulphate, or intravesical instillation therapy, were included. Staging was done based on symptoms, bladder pain, and quality of life. Matched controls were carefully selected...
considering age, menopausal status, hormone use et al. Bladder biopsies were performed before procedures such as hydrodistention or fulguration. Biopsy sites included lateral walls, dome, posterior wall of bladder wall, but not from trigone, for both IC patients and controls.

ARID1A immunohistochemistry (IHC) and scoring system. IHC analysis for ARID1A expression was performed on 5-μm slides using a polyclonal rabbit anti-ARID1A antibody (1:250, HPA005456; Sigma-Aldrich). Antigen retrieval was performed by submerging the tissue sections in citrate buffer (pH 6.0) and then in a steamer for 10 minutes. The sections were then incubated with the rabbit antibody at a dilution of 1:200 at 4 °C overnight. A positive reaction was detected by the EnVision + System (Dako).

Statistics. All data were generated from experiments performed at least three times and expressed as mean ± standard deviation (SD). The student’s t-tests were used to determine the statistical significance of differences between samples treated under different conditions. Differences were considered statistically significant when p < 0.05 (*), p < 0.01 (**), or p < 0.001 (***).

Results α-OG, an IC-associated metabolite, suppresses cell proliferation in immortalized normal human bladder-derived epithelial cells. In light of our previous global metabolomics data linking α-OG to cell cycle arrest and proliferation suppression16, we first investigated the effects of α-OG in immortalized normal bladder epithelial cells. Cell cycle transition and proliferation were measured in TRT-HU1 cells treated with or without 10 mM of α-OG. Consistent with previous reports, we observed significant suppression of cell proliferation in response to α-OG (Fig. 1A). Western blot analysis was performed to ascertain the involvement of several key cell cycle and proliferation regulators. We found that levels of p53 and p21 significantly increased while levels of JunB modestly increased in the presence of α-OG (Fig. 1B).
α-OG perturbed the epigenetic architecture of immortalized normal bladder epithelial cells. Given previous reports demonstrating that α-OG modulates epigenetic regulation, we next tested our hypothesis that the global DNA methylome is altered in response to α-OG in immortalized normal human bladder epithelial cells. In order to assess whether the DNA methylome is changed by α-OG, EPIC array was performed. Our workflow is described in Fig. 2. Our analysis and data requisition resulted in differentially methylated genes (DMGs) in response to α-OG (Supplementary Table 2–4).

Using the results from the quality control (QC) test, density plots for probes were constructed for DNA methylation levels in control and α-OG treated conditions. Untreated control samples (in orange) showed a slight hypermethylation pattern. The α-OG-treated samples (in green) showed a more even distribution of beta values across probes. The upper plot defines differential methylation based on statistical significance alone (Group A – hypomethylated probes: p < 0.0005, Group B – hypermethylated probes: p < 0.0005). The lower plot shows the exact same volcano plot, but defines differential methylation based on both statistical significance and β-value difference (Group C - hypermethylated probes: p < 0.05 and β-value difference > 0.1, Group D - hypomethylated probes: p < 0.05 and β-value difference > 0.1).

Following the QC steps within minfi (Fig. 3A, B), methylation data for 836,329 CpGs were analyzed. Because we were unable to use minfi’s stringent cutoffs to identify Differentially methylated regions (DMRs) with Bumphunter and dmpFinder, we opted to do our analysis using quantitative cutoffs, splitting into four groups of probes. The resulting volcano plots show the differentially methylated probes present between α-OG treatment and control conditions. Significantly hyper-methylated probes are shown in orange, while hypo-methylated probes are shown in blue. First, the most statistically robust CpGs were selected using a p-value cutoff of 0.0005. Unexpectedly, the most significant probes had the smallest differences in methylation β-values (β < 0.1). These probes show...
two cutoffs yielded two groups, Group A and B, shown in Fig. 3C, as having 873 and 382 probes, respectively. The other two groups (C and D) were identified by looking at the largest difference in $\beta$-values present, $\beta > 0.1$. These probes were less statistically significant, with a p-value < 0.05. Group C only had 32 probes while Group D had 366. Overall, our analysis of probes that were most statistically significant and had the greatest magnitude of change showed a general shift towards increased global hypo-methylation. Based on these results, we opted to further analyze the groups that had the largest changes in $\beta$-values, focusing mostly on group D due to the limited number of probes in group C.

Gene tables for the groups with the largest numbers of identified probes, group A, B, and D, can be found in Supplementary Tables 2, 3, and 4, respectively. Heatmaps of all four groups of probes are shown in Fig. 3D. The heatmaps demonstrate a trend of increased hypo-methylation in probes of cells treated with $\alpha$-OG, particularly in Group D.

Biological meanings of DMGs responsive to $\alpha$-oxoglutarate. In order to explore the contribution of DNA methylation signatures in IC, we performed functional enrichment analysis and network modeling on the DMGs. Enriched cellular processes and biological pathways perturbed by $\alpha$-OG treatment were identified by using DAVID software\(^{25}\). Hypo-methylated genes were enriched for cell-cell adhesion, cell projection organization, neuron projection development, cell cycle processes, chromatin remodeling, and Rho protein signal transduction regulation, while cellular responses to stress, Ras GTPase activity, and transport of NADH to ubiquinone in the mitochondrial electron transport chain were enriched for by hyper-methylated genes (Fig. 4A). We also found that KEGG pathways, inositol phosphate metabolism, glycosylphosphatidylinositol-anchor biosynthesis, leukocyte trans-endothelial migration, phosphatidylinositol signaling were enriched for by hypo-methylated genes and endocytosis, Alzheimer's disease, oxidative phosphorylation, Huntington's disease were enriched for by hyper-methylated genes (Fig. 4B). Table 1 shows the related DMGs for each of the enriched cellular processes.
Our previous study on RNA-sequencing analysis of a IC rat mimic model revealed significant association of cell adhesion and IC context. In addition, gene expression changes of chromatin remodeling genes were identified in human bladder epithelial cells from patients with IC. We thus focused on cell-cell adhesion and

Figure 5. The expression levels of ARID1A were significantly increased in α-OG treated condition. (A) Quantification result from RT-PCR analysis to measure the gene expression levels of six candidate genes (ARID1A, HDAC4, PKD1, β-CATENIN, SMARCA2, and PBRM1) in the presence or absence of α-OG. *P < 0.05 (two-sided Student's t-test). (B) Representative western blot show the levels of candidates (ARID1A, HDAC4, PKD1, β-CATENIN, SMARCA2, and PBRM1) and β-actin. (C) DNMT and (D) TET activity were measured in response to α-OG treatment. *P < 0.05 (two-sided Student's t-test). (E) Representative Immunohistochemical stain showed ARID1A expression in bladder tissues obtained from IC patients (IC) and healthy donors (C). (F) A diagram showing the potential mechanism that redundant α-OG in urine may regulate bladder epithelial cells and contribute to suppression of cell proliferation.
Table 1. Lists of DMGs for each of the enriched cellular processes.

| Term                                      | Hypo-methylated genes                                                                 | Hyper-methylated genes                                                                 |
|-------------------------------------------|---------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| cell-cell adhesion                        | PCDHG8, PCDHG8, PCDHG7, PCDHG6, PCDHG5, PCDHG4, PCDHG3, PCDHG2, CTNNB1, PCDHG1, CLDN15, PCDHG1, NPH4P, FAT1, COL6A2, PKD1, DLG1, PCDHG12, PCDHG10, PCDHG11, PCDHG87, CLDN22, PCDHG86, PCDHG85, CERCAM, PCDHG82, PCDHG85, PCDHG84, CDH13, CDH18 | CDS5R1, PARD3, EZR, CTNNB2, PTPRT                                                         |
| cell projection organization              | ADORA2A, PX6, GRIN3A, TP44, EPHB1, VCL, DBN31, IGF1, HOX2A, ATXN10, BCL1L1B, NUMB, DCLK1, PRKCA, MCF2, BAIAP2L1, BAIAP2, RRX2, NUP95, WWTR1, CDH13, TSCI, CYFIP1, MAPKIP3, EFNA5, APB82, APB81, DST, NFG, MYH10 | PPP1R9B, PARDDB, CDS5R1, PARD3, ILK, NUMB, SIAH1, LMX1A, FEZ1                          |
| neuron projection development             | PRKCA, ADORA2A, MCF2, BAIAP2, RRX2, PX6, GRIN3A, EPHB1, EFNA5, HOX2A, ATXN10, BCL1L1B, NUMB, MAPKIP3, CYFIP1, EFNA5, APB82, APB81, DST, DCLK1, MYH10, NFG | PPP1R9B, PARDDB, CDS5R1, PARD3, ILK, NUMB, SIAH1, LMX1A, FEZ1                          |
| cell cycle process                        | MAD1L1, FZ1F, KIF25, TSG101, POLA1, CETN1, CDC34, CDC16, TCF7L2, CTNNB1, PLAGI1, PSDF1, CUL2, RAD51L1, PSMD1, PBRM1, PKD1, HBPI, PSMD5, TCF3, ZW10, PSMD9, NEAT1, RAD52, WEE1, FOXN3, PPM1G, MNAT1, PPM1D, NOLC1, CUL4A, SYCP3, CDSKKAP, CDK11B, HORMAD1, CHFR, APB82, APB81, DST, MYH10 | KIFC1, KIF22, DAXX, TCF7L2, CENP1, DDT3, PPP1R9B, KIF3C, CUL5, CUL4A, ILK, SKA2, PSMD4, MAPRE1, MAP9, DHCR24 |
| chromatin remodeling                      | HDAC4, SATB2, SYCP3, PBRM1, ARID1A, SMARCA2, RERE, SMARCA4 | BAZ1B, SUPT5H                                                                           |
| regulation of Rho protein signal transduction | OBCSN, BCR, PLEKHG1, ABR, TSCI, PLEKHG7, MCF2, ARHGEF16, TR10, ABR, FAPR1 | PREX2, BCL6, MLST8, ARHGEF11                                                          |
| actin cytoskeleton organization          | FMNL2, SHROOM3, TXN4B, SSH1, CALD1, CYTH2, MYO9B, DAAM1, TP51, ARHGAPO6, NPH4P, SCIN, GRID2IP, DST, LCP1, MYH10, CDC42BBP, DLG1 | PPP1R9B, EZR, BCL6, FHDC1, ARHGEF1                                                   |
| regulation of cellular response to stress | SH3RF1, MAP3K9, MAP3K10, MAPKIP3, PKN1 | FGF19, ERC6C, AIDA, POLH, EEF1F1, HIK3, DAXX, SPPI                                       |
| regulation of Ras GTPase activity        | TBC1D2B, TSCI, TBC1D14, RABGAP1L, AGAPI | RABGAP1L, ASAP1, BCL6, ETV5, MLST8, TBC1D20, AGAP2                                        |
| mitochondrial electron transport, NADH to ubiquinone |                                                   | NDUF5S7, NDUF8S10, NDUF10, NDUF5S1                                                       |

chromatin remodeling. To end a network model describing the interactions of the hypo-methylated genes involved in cell–cell adhesion and chromatin remodeling were reconstructed with protein–protein interaction information from the STRING database26. This network model consisted of β-CATENIN (CTNNB1), PKD1 (polycystin 1), CDH18 (cadherin 18), SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4), HDAC4 (histone deacetylase 4), ARID1A (AT-rich interactive domain 1A), PBRM1 (Polybromo-1, a component of the PBAF (Polybromo-associated-BRG1- or BRM-associated factors) chromatin remodeling complex) et al. Of note, CTNNB1 and SMARCA4 are valid candidates regulating cell adhesion and chromatin remodeling in this system (Fig. 4C).

ARID1A expression significantly increased with α-OG treatment. ARID1A, HDAC4, PKD1, β-CATENIN, SMARCA2, and PBRM1 were suggested in our network model for IC and were selected for further validation. These genes were all hypo-methylated in response to α-OG treatment. To ascertain that α-OG treatment modifies the DNA methylome in TRT-HU1 cells, we next quantified the levels of DNA methylation and gene expression of the targeted candidate genes. Using quantitative RT-PCR analysis with customized primers (Supplementary Table 1), we found the mRNA expression levels of all candidate genes as being slightly elevated. Gene expression of ARID1A was significantly increased in the α-OG treated condition (p = 0.018) (Fig. 5A). The Protein expression levels of ARID1A and SMARCA2 increased; however, those of HDAC4, PDK, β-CATENIN, and PBRM1 did not (Fig. 5B).

α-OG treatment altered the activity of ten-eleven translation (TET) hydroxylase but not DNA methyltransferase (DNMT). To further elaborate on the effects of α-OG on epigenetic regulation in immortalized normal bladder epithelial cells, we measured the activity of two DNA methylation regulators, DNMT and TET, in the presence of α-OG (Fig. 5C). In our experiments, α-OG treatment suppressed TET activity almost completely; however, there was no influence on DNMT activity (Fig. 5D).

On histological examination, we found that ARID1A expression greatly increased in IC patients. IHC analysis of bladder tissue samples obtained from 10 IC patients and 10 normal controls showed 100% positive staining for ARID1A, while none of the control tissue showed any staining (Fig. 5E). A hypothetical diagram suggesting epigenetic modulation on ARID1A by α-OG is shown in Fig. 5F.

Discussion
Our previous reports provided evidence showing that bladder cell metabolism is altered in IC and suggested several urinary metabolites, including α-OG, as candidate biomarkers16. However, it is still unclear whether these metabolic biomarkers are biologically active in urine and how they contribute to bladder pathogenesis and homeostasis. The metabolic changes in the IC bladder are largely speculated to be associated with the microenvironment, resulting in altered oxygen states and metabolites. As products of this perturbed metabolism, these metabolites may be what are mediating the epigenetic alteration seen in the IC bladder. Here, our experimental results demonstrate that a novel IC biomarker, α-OG, directly reduces TET activity. α-OG also simultaneously

Table 1. Lists of DMGs for each of the enriched cellular processes.
causes DNA hypo-methylation of ARID1A and cell cycle transition arrest in immortalized normal bladder epithelial cells (Fig. 5F). These findings are consistent with clinical observations in patients; one characteristic of IC is thin bladder epithelium layers31,32. Previous mechanistic studies have shown that bladder epithelial cells derived from IC patients have suppressed proliferation and cell cycle arrest31,33. Based on these previous observations and our findings, α-OG may not only be a novel urinary metabolite associated with IC, but may also have an active biological function.

Altering the methylation status of DNA promoters and enhancers is widely linked to reductions in gene transcription. There are two main processes that orchestrate DNA methylation of key epigenetic regulators; these involve 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), which are located on the CpG islands of gene promoters and enhancers. Currently, the most well-studied process of covalent DNA modification is methylation through the addition of methyl groups to produce 5mC. Active DNA methyltransferases, such as DNMT1 and DNMT3A/B, use S-adenosylmethionine as methyl donors and are required for establishing and maintaining DNA methylation patterns. DNA demethylation is another important epigenetic mechanism and is mediated by TET, which converts 5mC to 5hmC and further to 5-carboxylcytosine (5-caC) through its hydroxylase activity.

In the context of IC, perturbed epigenetic architectures, such as DNA methylation and demethylation, in the bladder epithelium have not been carefully investigated. However, given that our encouraging data shows suppressed TET activity as a potential IC biomarker, it may be clinically significant to elaborate on the potential role of TET and its targets as diagnostic markers and/or therapeutic targets. It is not known how these changes in TET and 5mC profiles are related to IC and how TET can be reactivated. What is known so far is that the TET family (TET1, TET2, and TET3) plays an important role in hydroxymethylating and demethylating 5mC in IC. It is still unclear how these changes in TET and 5mC profiles are related to IC and how TET can be reactivated. Unfortunately, due to the lack of commercially available TET activators, we could not perform any tests to see if TET stimulation can reverse bladder dysfunction.

Our results also suggest the possible physiological role of ARID1A in maintaining normal homeostasis in the bladder epithelium through controlling chromatin remodeling. ARID1A and SMARCA2, both are subunits of the SWI/SNF chromatin-remodeling complex, were suggested as key players of α-OG signaling pathway in our network model. Although modest, the expression of SMARCA2 also increased upon α-OG treatment (Fig. 5B). This finding is consistent with previously published microarray analyses of IC primary culture cells and controls. The gene expression of both IC patient-derived primary culture cells and APF (anti-proliferative factor, an urinary IC biomarker)-treated cells suggested a less proliferative phenotype, with increased expression of SMARCA234.

ARID1A sustains chromatin accessibility through H3K27me3 and H3K27ac in the enhancer regions35,36. ARID1A is also a well-known bona fide tumor suppressor that is frequently inactivated by mutations or reduced in expression due to promoter hyper-methylation37. Along with p21, cyclins, and E2F-responsive genes, ARID1A is essential for normal cell cycle arrest; thus, inactivation of ARID1A results in tumor transformation, metastasis, and/or drug resistance38,39. However, the biological function of ARID1A is context dependent. In bladder cancer, increased ARID1A expression is generally correlated with higher tumor grade; however, there is some variation based on the cancer type40,41. Detailed information regarding the mechanism and physiological roles of ARID1A and its co-factors has been lacking. Based on our study, we propose that ARID1A can be regulated through α-OG, contributing to an impaired cell proliferation in IC. We believe that additional attempts to validate the epigenetic regulation of α-OG on ARID1A in clinical samples may provide novel insight into the etiology of IC and identify metabolites that can serve as IC biomarkers for clinical application.

In summary, evidence from our EPIC DNA methylation profiling suggests that α-OG, a potential IC biomarker candidate, regulates ARID1A epigenetically. Modification of the promoter for ARID1A contributes to increased expression at both the mRNA and protein levels, leading to suppressed proliferation in the bladder epithelial cells. These findings indicate that urinary metabolites in the bladder can lead to epigenetic reprogramming. Given our observations, we may have defined the epigenetic regulatory mechanisms of ARID1A and TET activity in the anti-proliferative axis in immortalized normal bladder epithelial cells.

References

1. Pflumm, M. Animal instinct helps doctors ferret out disease. Nature medicine 17, 143, https://doi.org/10.1038/nm0211-143 (2011).
2. Hanno, P., Keasy, S., Moldwin, R. & Van Ophoven, A. International Consultation on IC - Rome, September 2004/Forging an International Consensus: progress in painful bladder syndrome/interstitial cystitis. Report and abstracts. International urology and urological science 16(Suppl 3), S2–S34, https://doi.org/10.1016/S0192-8655(05)-1301-x (2005).
3. Hanno, P. et al. Diagnosis of interstitial cystitis. The Journal of urology 143, 278–281 (1990).
4. Uzzo, R., Cass, A. & Hanno, P. Interstitial cystitis: pathogenesis, diagnosis and treatment. Nature reviews Urology 2, 318–324, https://doi.org/10.1038/nruro.2005.167 (2005).
5. Nordling, J. et al. Primary evaluation of patients suspected of having interstitial cystitis (IC). European urology 45, 662–669, https://doi.org/10.1016/j.eururo.2003.11.021 (2004).
6. Warren, J. W. & Keay, S. Interstitial cystitis. Current opinion in urology 12, 69–74 (2002).
7. Anger, J. T. et al. Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome. International urology and urological cancer journal 22, 395–400, https://doi.org/10.1016/S0019-0120-1322-8 (2011).
8. Berry, S. H. et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. The journal of urology 186, 540–544, https://doi.org/10.1016/j.juro.2011.03.132 (2011).
9. Suskind, A. M. et al. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study. The Journal of urology 189, 141–145, https://doi.org/10.1016/j.juro.2012.08.088 (2013).
10. Berry, S. H. et al. Development, validation and testing of an epidemiological case definition of interstitial cystitis/painful bladder syndrome. The journal of urology 183, 1848–1852, https://doi.org/10.1016/j.juro.2010.12.103 (2010).
11. Clemens, J. Q. et al. Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary pain in both men and women. Urology 74, 983–987, quiz 987 e981-983, https://doi.org/10.1016/j.urology.2009.06.078 (2009).
12. Bogart, L. M., Berry, S. H. & Clemens, J. Q. Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review. The Journal of urology 177, 450–456, https://doi.org/10.1016/j.juro.2006.09.032 (2007).
13. Zhang, A., Sun, H. & Wang, X. Serum metabolomics as a novel diagnostic approach for disease: a systematic review. *Analytical and bioanalytical chemistry* **404**, 1239–1245, https://doi.org/10.1007/s00216-012-6117-1 (2012).

14. Gebregziorgis, T. & Powers, R. Application of NMR metabolomics to search for human disease biomarkers. *Combinatorial chemistry & high throughput screening* **15**, 595–610 (2012).

15. Serkova, N. J. & Brown, M. S. Quantitative analysis in magnetic resonance spectroscopy: from metabolic profiling to in vivo biomarkers. *Bioanalysis* **4**, 321–341, https://doi.org/10.4155/bio.11.323 (2012).

16. Wen, H. et al. Urinary Metabolite Profiling Combined with Computational Analysis Predicts Intestinal Cystitis-Associated Candidate Biomarkers. *Journal of proteome research*. https://doi.org/10.1021/pr5007729 (2014).

17. Vatrinet, R. et al. The alpha-ketoglutarate dehydrogenase complex in cancer metabolic plasticity. *Cancer & metabolism* **5**, 3, https://doi.org/10.1186/s12957-017-0165-0 (2017).

18. Xu, T. et al. Metabolic control of TH17 and induced Treg cell balance by an epigenetic mechanism. *Nature* **548**, 228–233, https://doi.org/10.1038/nature23475 (2017).

19. Kim, J. et al. An INTR-IMMUT-converted human urothelial cell line that responds to anti-proliferative factor. *In vitro cellular & developmental biology. Animal* **47**, 2–9, https://doi.org/10.1626/s11626-010-9350-y (2011).

20. Zhou, W., Laird, P. W. & Shen, H. Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes. *Nucleic acids research* **45**, e22, https://doi.org/10.1093/nar/gkw967 (2017).

21. Fortin, J. P., Triche, T. J. Jr, & Hansen, K. D. Preprocessing, normalization and quality control analysis of the Illumina HumanMethylationEPIC array with minfi. *Bioinformatics* **33**, 558–560, https://doi.org/10.1093/bioinformatics/btw691 (2017).

22. Triche, T. J. Jr, Weisenberger, D. J., Van Den Berg, D., Laird, P. W. & Siegmund, K. D. Low-level processing of Illumina Infinium DNA Methylation BeadArrays. *Nucleic acids research* **41**, e90, https://doi.org/10.1093/nar/gkt090 (2013).

23. Colaprico, A. et al. TCGAbiolinks: an R/bioconductor package for integrative analysis of TCGA data. *Nucleic acids research* **44**, e71, https://doi.org/10.1093/nar/gkv1507 (2015).

24. Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* **32**, 2847–2849, https://doi.org/10.1093/bioinformatics/btw313 (2016).

25. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nature protocols* **4**, 44–57, https://doi.org/10.1038/nprot.2008.211 (2009).

26. Soklarczyk, D. et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. *Nucleic acids research* **45**, D362–D368, https://doi.org/10.1093/nar/gkw937 (2017).

27. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome research* **13**, 2498–2504, https://doi.org/10.1101/gr.139303 (2003).

28. Hanno, P. M. et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. *The Journal of urology* **185**, 2162–2170, https://doi.org/10.1016/j.juro.2011.03.004 (2011).

29. Hanno, P. M., Erickson, D., Moldwin, R., Faraday, M. M. & American Urological, A. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. *The Journal of urology* **193**, 1545–1553, https://doi.org/10.1016/j.juro.2015.01.086 (2015).

30. Choi, B. H. et al. Differential perturbation of the interstitial cystitis-associated genes of bladder and urethra in rat model. *Cell cycle* **16**, 749–758, https://doi.org/10.2115/cc103265 (2017).

31. Kim, J., Keay, S. K., Dimitrokov, J. D. & Freeman, M. R. p53 mediates interstitial cystitis proapoptotic factor (APF)-induced growth inhibition of human urothelial cells. *FEBS letters* **581**, 3795–3799, https://doi.org/10.1016/j.febslet.2007.06.058 (2007).

32. Tomaszewska, J. E. et al. Biopsy features are associated with primary symptoms in interstitial cystitis: results from the interstitial cystitis database study. *Urology* **57**, 67–81 (2001).

33. Keay, S., Zhang, C. O., Shoenfelt, J. L. & Chai, T. C. Decreased in vitro proliferation of bladder epithelial cells from patients with interstitial cystitis. *Urology* **61**, 1278–1284 (2003).

34. Keay, S., Seililler-Moiseiwitsch, F., Zhang, C. O., Chai, T. C. & Zhang, J. Changes in human bladder epithelial cell gene expression associated with interstitial cystitis or proapoptotic factor treatment. *Physiological genomics* **14**, 107–115, https://doi.org/10.1152/physiolgenomics.00055.2003 (2003).

35. Hodges, C., Kirkland, J. G. & Crabtree, G. R. The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. *Cold Spring Harbor perspectives in medicine* **6**, https://doi.org/10.1101/cshperspect.a026930 (2016).

36. Wilson, B. G. & Roberts, C. W. SWI/SNF nucleosome remodelers and cancer. *Nature reviews. Cancer* **11**, 481–492, https://doi.org/10.1038/nrc3068 (2011).

37. Wu, J. N. & Roberts, C. W. ARID1A mutations in cancer: another epigenetic tumor suppressor? *Cancer discovery* **3**, 37–48, https://doi.org/10.1158/2159-8290.CD-12-0361 (2013).

38. Shain, A. H. et al. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. *Proceedings of the National Academy of Sciences of the United States of America* **109**, E252–259, https://doi.org/10.1073/pnas.1114817109 (2012).

39. Wang, K. et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. *Nature genetics* **43**, 1219–1223, https://doi.org/10.1038/ng.982 (2011).

40. Faraj, S. E. et al. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. *Human pathology* **45**, 2233–2239, https://doi.org/10.1016/j.humpath.2014.07.003 (2014).

41. Li, J., Lu, S., Lombardo, K., Monahan, R. & Amin, A. ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma. *Human pathology* **55**, 17–23, https://doi.org/10.1016/j.humpath.2016.04.006 (2016).

**Acknowledgements**

The authors acknowledge support from Florida Department of Health, Bankhead-Coley Cancer Research Program (5BC03) (to M.K.), National Institutes of Health grants (1U01DK103260, 1R01DK100974, U24 DK097154, NIH NCATS UCLA CTSA UL1TR000124), Department of Defense grants (W81XWH-15-1-0415), Centers for Disease Controls and Prevention (1U01DP006079), IMAGINE NO IC Research Grant, the Steven Spielberg Discovery Fund in Prostate Cancer Research Career Development Award, the U.S.-Egypt Science and Technology joint Fund (to J.K.). J.K. is former recipient of Intestinal Cystitis Association Pilot Grant, a Fishbein Family IC Research Grant, New York Academy of Medicine, and Boston Children’s Hospital Faculty Development. The funders had no role in the design, data collection and analysis, decision to publish or preparation of the manuscript. In addition, this article is derived from the Subject Data funded in whole or part by NAS and USAID. Any opinions, findings, conclusions, or recommendations expressed in such article are those of the authors alone, and do not necessarily reflect the views of USAID or NAS.

**Author Contributions**

M.S. and A.Y. involved and performed most of the experiments. N.Y., S.Y., and M.K. performed DNA methylation analysis and helped to draft paper. A.Y., E.C., H.S.Y., and J.B. performed immunohistochemical works. M.S.,
A.Y., and E.C. performed biochemical and functional analysis in vitro. H.Y. and M.K. provided IHC images and provided clinical insights. B.B. supported EPIC data interpretation and provided scientific comments on project. J.K. designed and conceived the study and wrote the paper. All authors discussed the results and commented on the manuscript at all stages, and read and approved the manuscript.

Additional Information

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018